Aviceda Therapeutics a late-stage, pre-clinical biotech company focused on developing the next generation of immuno-modulators by harnessing the power of glycobiology to manipulate the innate immune system and chronic, non-resolving inflammation, is announcing additional members of its Scientific Advisory Board who will help shape ongoing research and development efforts.

"It is critical that the biotechnology industry and academic institutions work together to develop therapeutics for diseases with significant unmet medical needs, and CCRC is an ideal partner to support us in this effort," said Mohamed Genead, M.D., Co-Founder & President and Chief Executive Officer. "CCRC at university of Georgia has an impressive track record of cutting-edge research in glycochemistry and glycobiology, as well as in innate immunity. We are excited to collaborate with CCRC in our efforts and look forward to build next generation glyco-therapeutics together."

CCRC lab will work together on this collaboration with Aviceda’s in house lab. "This project will be our highest priority for the group in the next few months as the goal is to support their preclinical studies and advance their lead asset towards FIH trials," Boons said.

"Our understanding of the role of glyco-immune responses in disease progression is rapidly increasing, providing insight into previously unknown or misunderstood cellular crosstalk. Working with CCRC, we will be at the forefront of developing new molecules that can modulate these interactions, providing profound therapeutic effects in a range of conditions underlined by inflammatory processes," said Michael Tolentino, M.D., Chief Technology Officer.